{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:47:50Z","timestamp":1786985270013,"version":"build-2736575974"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,9]],"date-time":"2024-10-09T00:00:00Z","timestamp":1728432000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004071","name":"Khon Kaen University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004071","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004704","name":"National Research Council of Thailand","doi-asserted-by":"publisher","award":["NRCT5-RGJ63003-065"],"award-info":[{"award-number":["NRCT5-RGJ63003-065"]}],"id":[{"id":"10.13039\/501100004704","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["22H03331"],"award-info":[{"award-number":["22H03331"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.biopha.2024.117569","type":"journal-article","created":{"date-parts":[[2024,10,17]],"date-time":"2024-10-17T02:40:23Z","timestamp":1729132823000},"page":"117569","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Buparlisib and ponatinib inhibit aggressiveness of cholangiocarcinoma cells via suppression of IRS1-related pathway by targeting oxidative stress resistance"],"prefix":"10.1016","volume":"180","author":[{"given":"Waleeporn","family":"Kaewlert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0145-8753","authenticated-orcid":false,"given":"Chadamas","family":"Sakonsinsiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Worachart","family":"Lert-itthiporn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panupong","family":"Mahalapbutr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saba","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thanyada","family":"Rungrotmongkol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7652-7771","authenticated-orcid":false,"given":"Apinya","family":"Jusakul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9465-4878","authenticated-orcid":false,"given":"Napat","family":"Armartmuntree","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chawalit","family":"Pairojkul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guofei","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7315-8835","authenticated-orcid":false,"given":"Ning","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Somchai","family":"Pinlaor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariko","family":"Murata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9001-1197","authenticated-orcid":false,"given":"Raynoo","family":"Thanan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.biopha.2024.117569_bib1","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/s41572-021-00300-2","article-title":"Cholangiocarcinoma","volume":"7","author":"Brindley","year":"2021","journal-title":"Nat. Rev. Dis. Prim."},{"issue":"5","key":"10.1016\/j.biopha.2024.117569_bib2","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1002\/jhbp.62","article-title":"Roles of liver fluke infection as risk factor for cholangiocarcinoma","volume":"21","author":"Sithithaworn","year":"2014","journal-title":"J. Hepatobiliary Pancreat. Sci."},{"issue":"2","key":"10.1016\/j.biopha.2024.117569_bib3","doi-asserted-by":"crossref","first-page":"450","DOI":"10.7150\/jca.68264","article-title":"The new insight of treatment in Cholangiocarcinoma","volume":"13","author":"Li","year":"2022","journal-title":"J. Cancer"},{"issue":"5","key":"10.1016\/j.biopha.2024.117569_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.aohep.2022.100737","article-title":"Clinical treatment of cholangiocarcinoma: an updated comprehensive review","volume":"27","author":"Elvevi","year":"2022","journal-title":"Ann. Hepatol."},{"issue":"1","key":"10.1016\/j.biopha.2024.117569_bib5","doi-asserted-by":"crossref","first-page":"193","DOI":"10.3390\/ijms16010193","article-title":"Oxidative stress and its significant roles in neurodegenerative diseases and cancer","volume":"16","author":"Thanan","year":"2014","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2024.117569_bib6","first-page":"956","article-title":"Oxidative stress concept updated: Definitions, classifications, and regulatory pathways implicated","volume":"20","author":"Lushchak","year":"2021","journal-title":"EXCLI J."},{"issue":"1","key":"10.1016\/j.biopha.2024.117569_bib7","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.bbrc.2015.06.112","article-title":"Development and characterization of a hydrogen peroxide-resistant cholangiocyte cell line: a novel model of oxidative stress-related cholangiocarcinoma genesis","volume":"464","author":"Thanan","year":"2015","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.biopha.2024.117569_bib8","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.redox.2017.11.011","article-title":"Prolonged oxidative stress down-regulates Early B cell factor 1 with inhibition of its tumor suppressive function against cholangiocarcinoma genesis","volume":"14","author":"Armartmuntree","year":"2018","journal-title":"Redox Biol."},{"issue":"3","key":"10.1016\/j.biopha.2024.117569_bib9","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24032428","article-title":"Overexpression of insulin receptor substrate 1 (IRS1) relates to poor prognosis and promotes proliferation, stemness, migration, and oxidative stress resistance in cholangiocarcinoma","volume":"24","author":"Kaewlert","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"9","key":"10.1016\/j.biopha.2024.117569_bib10","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.7150\/jca.52378","article-title":"Promoter hypermethylation of early B cell factor 1 (EBF1) is associated with cholangiocarcinoma progression","volume":"12","author":"Armartmuntree","year":"2021","journal-title":"J. Cancer"},{"issue":"6","key":"10.1016\/j.biopha.2024.117569_bib11","doi-asserted-by":"crossref","first-page":"3637","DOI":"10.1007\/s13277-013-0945-2","article-title":"Increased activation of PI3K\/AKT signaling pathway is associated with cholangiocarcinoma metastasis and PI3K\/mTOR inhibition presents a possible therapeutic strategy","volume":"34","author":"Yothaisong","year":"2013","journal-title":"Tumor Biol."},{"issue":"5","key":"10.1016\/j.biopha.2024.117569_bib12","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1016\/j.jhep.2004.07.016","article-title":"Enhanced epidermal growth factor receptor activation in human cholangiocarcinoma cells","volume":"41","author":"Yoon","year":"2004","journal-title":"J. Hepatol."},{"key":"10.1016\/j.biopha.2024.117569_bib13","doi-asserted-by":"crossref","DOI":"10.1177\/1758835920940948","article-title":"Targeting the FGFR signaling pathway in cholangiocarcinoma: promise or delusion?","volume":"12","author":"Wang","year":"2020","journal-title":"Ther. Adv. Med Oncol."},{"issue":"12","key":"10.1016\/j.biopha.2024.117569_bib14","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2015.363","article-title":"Effects of PI3K inhibitor NVP-BKM120 on overcoming drug resistance and eliminating cancer stem cells in human breast cancer cells","volume":"6","author":"Hu","year":"2015","journal-title":"Cell Death Dis."},{"issue":"6","key":"10.1016\/j.biopha.2024.117569_bib15","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0179948","article-title":"BKM120 induces apoptosis and inhibits tumor growth in medulloblastoma","volume":"12","author":"Zhao","year":"2017","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.biopha.2024.117569_bib16","first-page":"1627","article-title":"Inhibitory effect of NVP-BKM120 on cholangiocarcinoma cell growth","volume":"16","author":"Padthaisong","year":"2018","journal-title":"Oncol. Lett."},{"issue":"3","key":"10.1016\/j.biopha.2024.117569_bib17","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1200\/JCO.2011.36.1360","article-title":"Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors","volume":"30","author":"Bendell","year":"2012","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.biopha.2024.117569_bib18","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/s13058-020-01354-y","article-title":"Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer","volume":"22","author":"Garrido-Castro","year":"2020","journal-title":"Breast Cancer Res."},{"issue":"4","key":"10.1016\/j.biopha.2024.117569_bib19","doi-asserted-by":"crossref","first-page":"266","DOI":"10.3892\/ol.2021.12527","article-title":"Research update on the anticancer effects of buparlisib","volume":"21","author":"Xing","year":"2021","journal-title":"Oncol. Lett."},{"issue":"12","key":"10.1016\/j.biopha.2024.117569_bib20","doi-asserted-by":"crossref","DOI":"10.3390\/cancers10120526","article-title":"Ponatinib inhibits multiple signaling pathways involved in STAT3 signaling and attenuates colorectal tumor growth","volume":"10","author":"Tan","year":"2018","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.biopha.2024.117569_bib21","doi-asserted-by":"crossref","first-page":"635","DOI":"10.2147\/OTT.S189391","article-title":"Ponatinib: a novel multi-tyrosine kinase inhibitor against human malignancies","volume":"12","author":"Tan","year":"2019","journal-title":"OncoTargets Ther."},{"issue":"4","key":"10.1016\/j.biopha.2024.117569_bib22","doi-asserted-by":"crossref","first-page":"5874","DOI":"10.18632\/oncotarget.11580","article-title":"Novel multiple tyrosine kinase inhibitor ponatinib inhibits bFGF-activated signaling in neuroblastoma cells and suppresses neuroblastoma growth in vivo","volume":"8","author":"Li","year":"2017","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.biopha.2024.117569_bib23","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1007\/s10637-021-01170-x","article-title":"A pilot study of Pan-FGFR inhibitor ponatinib in patients with FGFR-altered advanced cholangiocarcinoma","volume":"40","author":"Ahn","year":"2022","journal-title":"Invest. New Drugs"},{"key":"10.1016\/j.biopha.2024.117569_bib24","doi-asserted-by":"crossref","DOI":"10.1177\/1073274821989314","article-title":"Intrahepatic cholangiocarcinoma: state of the art of FGFR Inhibitors","volume":"28","author":"Wu","year":"2021","journal-title":"Cancer Control"},{"issue":"3","key":"10.1016\/j.biopha.2024.117569_bib25","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1007\/s13577-020-00334-w","article-title":"Functional and genetic characterization of three cell lines derived from a single tumor of an Opisthorchis viverrini-associated cholangiocarcinoma patient","volume":"33","author":"Sripa","year":"2020","journal-title":"Hum. Cell"},{"issue":"22","key":"10.1016\/j.biopha.2024.117569_bib26","doi-asserted-by":"crossref","first-page":"3392","DOI":"10.3748\/wjg.v11.i22.3392","article-title":"M. Miwa, Establishment and characterization of an opisthorchiasis-associated cholangiocarcinoma cell line (KKU-100)","volume":"11","author":"Sripa","year":"2005","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.biopha.2024.117569_bib27","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0065-2571(84)90007-4","article-title":"Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors","volume":"22","author":"Chou","year":"1984","journal-title":"Adv. Enzym. Regul."},{"issue":"2","key":"10.1016\/j.biopha.2024.117569_bib28","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","article-title":"Drug combination studies and their synergy quantification using the Chou-Talalay method","volume":"70","author":"Chou","year":"2010","journal-title":"Cancer Res."},{"issue":"5","key":"10.1016\/j.biopha.2024.117569_bib29","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/S0092-8674(00)81236-2","article-title":"Structure of the IRS-1 PTB domain bound to the juxtamembrane region of the insulin receptor","volume":"85","author":"Eck","year":"1996","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.biopha.2024.117569_bib30","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1038\/nsb0496-388","article-title":"Structural basis for IL-4 receptor phosphopeptide recognition by the IRS-1 PTB domain","volume":"3","author":"Zhou","year":"1996","journal-title":"Nat. Struct. Biol."},{"key":"10.1016\/j.biopha.2024.117569_bib31","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/165879","article-title":"Nuclear localization of COX-2 in relation to the expression of stemness markers in urinary bladder cancer","author":"Thanan","year":"2012","journal-title":"Mediat. Inflamm. 2012"},{"issue":"D1","key":"10.1016\/j.biopha.2024.117569_bib32","doi-asserted-by":"crossref","first-page":"D1334","DOI":"10.1093\/nar\/gkab970","article-title":"OncoDB: an interactive online database for analysis of gene expression and viral infection in cancer","volume":"50","author":"Tang","year":"2022","journal-title":"Nucleic Acids Res."},{"issue":"10","key":"10.1016\/j.biopha.2024.117569_bib33","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1158\/2159-8290.CD-17-0368","article-title":"Whole-genome and epigenomic landscapes of etiologically distinct subtypes of cholangiocarcinoma","volume":"7","author":"Jusakul","year":"2017","journal-title":"Cancer Discov."},{"issue":"11","key":"10.1016\/j.biopha.2024.117569_bib34","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aau0731","article-title":"Ponatinib (AP24534) inhibits MEKK3-KLF signaling and prevents formation and progression of cerebral cavernous malformations","volume":"4","author":"Choi","year":"2018","journal-title":"Sci. Adv."},{"key":"10.1016\/j.biopha.2024.117569_bib35","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.2147\/DDDT.S250061","article-title":"In vitro and in vivo anti-tumor effects of Pan-HER inhibitor varlitinib on cholangiocarcinoma cell lines","volume":"14","author":"Dokduang","year":"2020","journal-title":"Drug Des. Devel. Ther."},{"issue":"9","key":"10.1016\/j.biopha.2024.117569_bib36","first-page":"4470","article-title":"Asciminib and ponatinib exert synergistic anti-neoplastic effects on CML cells expressing BCR-ABL1 (T315I)-compound mutations","volume":"11","author":"Gleixner","year":"2021","journal-title":"Am. J. Cancer Res."},{"issue":"6","key":"10.1016\/j.biopha.2024.117569_bib37","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1007\/s10637-015-0298-3","article-title":"A phase I trial of mFOLFOX6 combined with the oral PI3K inhibitor BKM120 in patients with advanced refractory solid tumors","volume":"33","author":"McRee","year":"2015","journal-title":"Invest. New Drugs"},{"issue":"24","key":"10.1016\/j.biopha.2024.117569_bib38","doi-asserted-by":"crossref","first-page":"3872","DOI":"10.1038\/sj.onc.1205513","article-title":"A p53-p66Shc signalling pathway controls intracellular redox status, levels of oxidation-damaged DNA and oxidative stress-induced apoptosis","volume":"21","author":"Trinei","year":"2002","journal-title":"Oncogene"},{"key":"10.1016\/j.biopha.2024.117569_bib39","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s12943-015-0354-9","article-title":"p66Shc as a switch in bringing about contrasting responses in cell growth: implications on cell proliferation and apoptosis","volume":"14","author":"Bhat","year":"2015","journal-title":"Mol. Cancer"},{"issue":"2","key":"10.1016\/j.biopha.2024.117569_bib40","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1002\/mas.21381","article-title":"Protein carbonylation as a major hallmark of oxidative damage: update of analytical strategies","volume":"33","author":"Fedorova","year":"2014","journal-title":"Mass Spectrom. Rev."},{"issue":"11","key":"10.1016\/j.biopha.2024.117569_bib41","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11111755","article-title":"The role of Nrf2 activity in cancer development and progression","volume":"11","author":"Zimta","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.biopha.2024.117569_bib42","doi-asserted-by":"crossref","DOI":"10.7717\/peerj.12750","article-title":"Therapeutic targeting of ARID1A and PI3K\/AKT pathway alterations in cholangiocarcinoma","volume":"10","author":"Tessiri","year":"2022","journal-title":"PeerJ"},{"issue":"10","key":"10.1016\/j.biopha.2024.117569_bib43","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1007\/s00432-010-0811-1","article-title":"Induction of MKP-1 prevents the cytotoxic effects of PI3K inhibition in hilar cholangiocarcinoma cells","volume":"136","author":"Leelawat","year":"2010","journal-title":"J. Cancer Res. Clin. Oncol."},{"issue":"60","key":"10.1016\/j.biopha.2024.117569_bib44","doi-asserted-by":"crossref","first-page":"6526","DOI":"10.18632\/oncotarget.27251","article-title":"Efficacy and safety of buparlisib, a PI3K inhibitor, in patients with malignancies harboring a PI3K pathway activation: a phase 2, open-label, single-arm study","volume":"10","author":"Piha-Paul","year":"2019","journal-title":"Oncotarget"},{"issue":"6","key":"10.1016\/j.biopha.2024.117569_bib45","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.3892\/or.2013.2386","article-title":"Novel FGFR inhibitor ponatinib suppresses the growth of non-small cell lung cancer cells overexpressing FGFR1","volume":"29","author":"Ren","year":"2013","journal-title":"Oncol. Rep."},{"issue":"7","key":"10.1016\/j.biopha.2024.117569_bib46","doi-asserted-by":"crossref","DOI":"10.3390\/molecules24071363","article-title":"Ponatinib inhibits proliferation and induces apoptosis of liver cancer cells, but its efficacy is compromised by its activation on PDK1\/Akt\/mTOR signaling","volume":"24","author":"Liu","year":"2019","journal-title":"Molecules"},{"key":"10.1016\/j.biopha.2024.117569_bib47","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s13578-019-0351-6","article-title":"Preclinical development of HQP1351, a multikinase inhibitor targeting a broad spectrum of mutant KIT kinases, for the treatment of imatinib-resistant gastrointestinal stromal tumors","volume":"9","author":"Liu","year":"2019","journal-title":"Cell Biosci."},{"issue":"1","key":"10.1016\/j.biopha.2024.117569_bib48","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1186\/s13046-020-01692-x","article-title":"Autophagic flux inhibition enhances cytotoxicity of the receptor tyrosine kinase inhibitor ponatinib","volume":"39","author":"Corallo","year":"2020","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"4","key":"10.1016\/j.biopha.2024.117569_bib49","first-page":"1937","article-title":"MEKK3 sustains EMT and stemness in pancreatic cancer by regulating YAP and TAZ transcriptional activity","volume":"38","author":"Santoro","year":"2018","journal-title":"Anticancer Res."},{"issue":"23","key":"10.1016\/j.biopha.2024.117569_bib50","doi-asserted-by":"crossref","first-page":"2729","DOI":"10.1101\/gad.1824509","article-title":"YAP1 is amplified and up-regulated in hedgehog-associated medulloblastomas and mediates Sonic hedgehog-driven neural precursor proliferation","volume":"23","author":"Fernandez","year":"2009","journal-title":"Genes Dev."},{"issue":"19","key":"10.1016\/j.biopha.2024.117569_bib51","doi-asserted-by":"crossref","first-page":"17206","DOI":"10.18632\/oncotarget.4043","article-title":"YAP is a critical oncogene in human cholangiocarcinoma","volume":"6","author":"Pei","year":"2015","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.biopha.2024.117569_bib52","doi-asserted-by":"crossref","first-page":"8401","DOI":"10.1038\/s41598-019-44835-7","article-title":"Overexpression of MAP3K3 promotes tumour growth through activation of the NF-kappaB signalling pathway in ovarian carcinoma","volume":"9","author":"Zhang","year":"2019","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.biopha.2024.117569_bib53","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/ni1014","article-title":"Differential regulation of interleukin 1 receptor and Toll-like receptor signaling by MEKK3","volume":"5","author":"Huang","year":"2004","journal-title":"Nat. Immunol."},{"issue":"1","key":"10.1016\/j.biopha.2024.117569_bib54","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1590\/abd1806-4841.20197326","article-title":"Study of tissue inflammatory response in different mice strains infected by dematiaceous fungi Fonsecaea pedrosoi","volume":"94","author":"Ogawa","year":"2019","journal-title":"Bras. Dermatol."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332224014550?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332224014550?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T23:23:10Z","timestamp":1778541790000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332224014550"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":54,"alternative-id":["S0753332224014550"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2024.117569","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Buparlisib and ponatinib inhibit aggressiveness of cholangiocarcinoma cells via suppression of IRS1-related pathway by targeting oxidative stress resistance","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2024.117569","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"117569"}}